Citations (69)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (22)
Sajesh K. Veettil, Vanessa Vincent, Taylor Shufelt, Emma Behan, M. Sakil Syeed, Ammarin Thakkinstian, David C. Young & Nathorn Chaiyakunapruk. (2023) Incremental net monetary benefit of biologic therapies in moderate to severe asthma: a systematic review and meta-analysis of economic evaluation studies. Journal of Asthma 60:9, pages 1702-1714.
Read now
Read now
Sara Alves, João Cavaleiro Rufo & José Crispim. (2023) Economic evaluation of biological treatments in patients with severe asthma: a systematic review. Expert Review of Pharmacoeconomics & Outcomes Research 23:7, pages 733-747.
Read now
Read now
Andriana I Papaioannou, Evangelia Fouka, Konstantinos Bartziokas, Maria Kallieri, Angelos Vontetsianos, Konstantinos Porpodis, Nikoletta Rovina, Stelios Loukides & Petros Bakakos. (2023) Defining response to therapy with biologics in severe asthma: from global evaluation to super response and remission. Expert Review of Respiratory Medicine 17:6, pages 481-493.
Read now
Read now
Xiaoling Wang, Honghao Fang, Kunling Shen, Tianyi Liu, Jipan Xie, Yuantao Liu, Peibei Wu, Yilin Chen, Jia Zhong, Eric Wu, Wei Zhou & Bin Wu. (2020) Cost-effectiveness analysis of double low-dose budesonide and low-dose budesonide plus montelukast among pediatric patients with persistent asthma receiving Step 3 treatment in China. Journal of Medical Economics 23:12, pages 1630-1639.
Read now
Read now
Elizabeth A Brooks, Marc Massanari, Nicola A Hanania & Daniel J Weiner. (2019) Cost-effectiveness of fractional exhaled nitric oxide (FeNO) measurement in predicting response to omalizumab in asthma. ClinicoEconomics and Outcomes Research 11, pages 301-307.
Read now
Read now
Jenny Lam, Joel W. Hay, Jonathan Salcedo & Nicholas J. Kenyon. (2019) A cost-effectiveness analysis of reslizumab in the treatment of poorly controlled eosinophilic asthma. Journal of Asthma 56:8, pages 872-881.
Read now
Read now
Bunchai Chongmelaxme, Nathorn Chaiyakunapruk & Piyameth Dilokthornsakul. (2019) Incorporating adherence in cost-effectiveness analyses of asthma: a systematic review. Journal of Medical Economics 22:6, pages 554-566.
Read now
Read now
Maria Kallieri, Andriana I. Papaioannou, Evgenia Papathanasiou, Polyxeni Ntontsi, Spyridon Papiris & Stelios Loukides. (2017) Predictors of response to therapy with omalizumab in patients with severe allergic asthma – a real life study. Postgraduate Medicine 129:6, pages 598-604.
Read now
Read now
Cibele Suzuki, Nilceia Lopes da Silva, Praveen Kumar, Purnima Pathak & Siew Hwa Ong. (2017) Cost-effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting. Journal of Medical Economics 20:8, pages 832-839.
Read now
Read now
Piyameth Dilokthornsakul, Nathorn Chaiyakunapruk & Jonathan D. Campbell. (2017) Does the use of efficacy or effectiveness evidence in cost-effectiveness analysis matter?. Journal of Asthma 54:1, pages 17-23.
Read now
Read now
Maxime Luu, Marc Bardou, Philippe Bonniaud & Françoise Goirand. (2016) Pharmacokinetics, pharmacodynamics and clinical efficacy of omalizumab for the treatment of asthma. Expert Opinion on Drug Metabolism & Toxicology 12:12, pages 1503-1511.
Read now
Read now
Thomas R. Einarson, Basil G. Bereza, T. Anders Nielsen, Jan Van Laer & Michiel E. H. Hemels. (2016) Systematic review of models used in economic analyses in moderate-to-severe asthma and COPD. Journal of Medical Economics 19:4, pages 319-355.
Read now
Read now
Thomas R. Einarson, Basil G. Bereza, T. Anders Nielsen & Michiel E. H. Hemels. (2015) Utilities for asthma and COPD according to category of severity: a comprehensive literature review. Journal of Medical Economics 18:7, pages 550-563.
Read now
Read now
Javier Domínguez-Ortega, Elsa Phillips-Anglés, Pilar Barranco & Santiago Quirce. (2015) Cost-effectiveness of asthma therapy: a comprehensive review. Journal of Asthma 52:6, pages 529-537.
Read now
Read now
Alberto Nahon Levy, Antonio J. García a Ruiz, Nuria García-Agua Soler & María Victoria Hidalgo Sanjuan. (2015) Cost-effectiveness of omalizumab in severe persistent asthma in Spain: a real-life perspective. Journal of Asthma 52:2, pages 205-210.
Read now
Read now
Floortje van Nooten, Sean Stern, Gert-Jan Braunstahl, Chris Thompson, Martijn Groot & Ruth E. Brown. (2013) Cost-effectiveness of omalizumab for uncontrolled allergic asthma in the Netherlands. Journal of Medical Economics 16:3, pages 342-348.
Read now
Read now
Girolamo Pelaia, Luca Gallelli, Teresa Renda, Pasquale Romeo, Maria Teresa Busceti, Rosa Daniela Grembiale, Rosario Maselli, Serafino Antonio Marsico & Alessandro Vatrella. (2011) Update on optimal use of omalizumab in management of asthma. Journal of Asthma and Allergy 4, pages 49-59.
Read now
Read now
Katayoun Bahadori, Bradley S Quon, Mary M Doyle-Waters, Carlo Marra & J Mark FitzGerald. (2010) A systematic review of economic evaluations of therapy in asthma. Journal of Asthma and Allergy 3, pages 33-42.
Read now
Read now
Thomas Sandström. (2009) Omalizumab in the management of patients with allergic (IgE-mediated) asthma. Journal of Asthma and Allergy 2, pages 49-62.
Read now
Read now
Dennis Keith Ledford. (2009) Omalizumab: overview of pharmacology and efficacy in asthma. Expert Opinion on Biological Therapy 9:7, pages 933-943.
Read now
Read now
Jean Bousquet, Raphael Chiron & Marc Humbert. (2008) Biologics in asthma: difficulties and drawbacks. Expert Opinion on Biological Therapy 8:12, pages 1921-1928.
Read now
Read now
Bruce M. Prenner. (2008) Asthma 2008: Targeting Immunoglobulin E to Achieve Disease Control. Journal of Asthma 45:6, pages 429-436.
Read now
Read now
Articles from other publishers (47)
Martina Orlovic, Tiziana Magni, Vasily Lukyanov, Ines Guerra & Alessandra Madoni. (2022) Cost-effectiveness of single-inhaler extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium in patients with uncontrolled asthma in England. Respiratory Medicine 201, pages 106934.
Crossref
Crossref
Ataru Igarashi, Harneet Kaur, Abhay Choubey, Akshay Popli, Madhusubramanian Muthukumar, Hajime Yoshisue, Minako Funakubo & Ken Ohta. (2022) Cost-Effectiveness Analysis of Omalizumab for Severe Allergic Asthma in Japan Using Real-World Evidence. Value in Health Regional Issues 27, pages 41-48.
Crossref
Crossref
Sung-Hyun Hong, Jeong-Yeon Cho, Tae-Bum Kim, Eui-Kyung Lee, Sun-Hong Kwon & Ju-Young Shin. (2021) Cost-Effectiveness of Tiotropium in Elderly Patients with Severe Asthma Using Real-World Data. The Journal of Allergy and Clinical Immunology: In Practice 9:5, pages 1939-1947.e7.
Crossref
Crossref
Pauline Azzano, Élise Dufresne, Thomas Poder & Philippe Bégin. (2020) Economic considerations on the usage of biologics in the allergy clinic. Allergy 76:1, pages 191-209.
Crossref
Crossref
Xiaoling Wang, Honghao Fang, Kunling Shen, Tianyi Liu, Jipan Xie, Yuantao Liu, Jia Zhong, Eric Wu, Wei Zhou & Bin Wu. (2020) The cost–effectiveness of low-dose budesonide as a Step 2 treatment for pediatric asthma in China. Journal of Comparative Effectiveness Research 9:16, pages 1141-1151.
Crossref
Crossref
Elida Duenas‐Meza, Luis F. Giraldo‐Cadavid, Elizabeth Karpf, Felipe Afanador, Olga L. Angarita, Oscar Barón, Maria S. Medina, Angelica Pachón, Angelica Gonzalez, Jenny Jurado & Carlos A. Torres‐Duque. (2020) Cost‐utility analysis of an integrated care program for children with asthma in a medium‐income country. Pediatric Pulmonology 55:11, pages 3110-3118.
Crossref
Crossref
Ioana Agache, Claudio Rocha, Jessica Beltran, Yang Song, Margarita Posso, Ivan Solà, Pablo Alonso‐Coello, Cezmi Akdis, Mubeccel Akdis, Giorgio W. Canonica, Thomas Casale, Tomas Chivato, Jonathan Corren, Stefano Del Giacco, Thomas Eiwegger, Davide Firinu, James E. Gern, Eckard Hamelmann, Nicola Hanania, Mika Mäkelä, Irene Hernández Martín, Parameswaran Nair, Liam O'Mahony, Nikolaos G. Papadopoulos, Alberto Papi, Hae‐Sim Park, Luis Pérez de Llano, Santiago Quirce, Joaquin Sastre, Mohamed Shamji, Jurgen Schwarze, Carlos Canelo‐Aybar, Oscar Palomares & Marek Jutel. (2020) Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma. Allergy 75:5, pages 1043-1057.
Crossref
Crossref
Solmaz Ehteshami-Afshar, Zafar Zafari, Nima Hamidi, J. Mark FitzGerald, Larry Lynd & Mohsen Sadatsafavi. (2019) A Systematic Review of Decision-Analytic Models for Evaluating Cost-Effectiveness of Asthma Interventions. Value in Health 22:9, pages 1070-1082.
Crossref
Crossref
Luis Manuel Entrenas Costa, Francisco Casas-Maldonado, José Gregorio Soto Campos, Alicia Padilla-Galo, Alberto Levy, Francisco Javier Álvarez Gutiérrez, Ana P. Gómez-Bastero Fernández, Concepción Morales-García, Rocío Gallego Domínguez, Gustavo Villegas Sánchez, Luis Mateos Caballero, Antonio Pereira-Vega, Cayo García Polo, Gerardo Pérez Chica & Juan José Martín Villasclaras. (2019) Economic Impact and Clinical Outcomes of Omalizumab Add-On Therapy for Patients with Severe Persistent Asthma: A Real-World Study. PharmacoEconomics - Open 3:3, pages 333-342.
Crossref
Crossref
Yee Vern Yong & Asrul Akmal Shafie. (2018) Using a dynamic adherence Markov model to assess the efficiency of Respiratory Medication Therapy Adherence Clinic (RMTAC) on asthma patients in Malaysia. Cost Effectiveness and Resource Allocation 16:1.
Crossref
Crossref
Zafar Zafari, Mohsen Sadatsafavi & J. Mark FitzGerald. (2018) Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US. Cost Effectiveness and Resource Allocation 16:1.
Crossref
Crossref
Karina Jahnz-Różyk, Joanna Lis, Marta Warchoł & Aleksandra Kucharczyk. (2018) Clinical and economic impact of a one-year treatment with omalizumab in patients with severe allergic asthma within a drug programme in Poland. BMC Pulmonary Medicine 18:1.
Crossref
Crossref
Carlos E. Rodriguez-Martinez, Monica P. Sossa-Briceño & Jose A. Castro-Rodriguez. (2018) Cost Effectiveness of Pharmacological Treatments for Asthma: A Systematic Review. PharmacoEconomics 36:10, pages 1165-1200.
Crossref
Crossref
August Generoso, Christine Muglia-Chopra & John Oppenheimer. (2018) Prospects for Monoclonal Antibody Therapy in Pediatric Asthma. Current Allergy and Asthma Reports 18:9.
Crossref
Crossref
R. Brett McQueen, Danielle N. Sheehan, Melanie D. Whittington, Job F. M. van Boven & Jonathan D. Campbell. (2018) Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations. PharmacoEconomics 36:8, pages 957-971.
Crossref
Crossref
Abir Al Said, Breda Cushen & Richard W Costello. (2017) Targeting patients with asthma for omalizumab therapy: choosing the right patient to get the best value for money. Therapeutic Advances in Chronic Disease 8:2-3, pages 31-45.
Crossref
Crossref
Girolamo Pelaia, Alessandro Vatrella & Rosario MaselliGirolamo Pelaia, Alessandro Vatrella & Rosario Maselli. 2017. Asthma: Targeted Biological Therapies. Asthma: Targeted Biological Therapies
27
49
.
A. S. Kolbin, L. S. Namazova-Baranova, E. A. Vishneva, M. Y. Frolov, T. L. Galankin, A. A. Alekseeva & E. A. Dobrynina. (2016) A Pharmaco-Economic Analyzis of Treating Severe Uncontrolled Child Asthma with Omalizumab — Actual Russian Clinical Practice Data. Pediatric pharmacology 13:4, pages 345-353.
Crossref
Crossref
María del Carmen Vennera, Antonio Valero, Estefany Uría, Carles Forné & César Picado. (2016) Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Persistent Asthma in Real Clinical Practice in Spain. Clinical Drug Investigation 36:7, pages 567-578.
Crossref
Crossref
Marieke Krol, Jocé Papenburg, Siok Swan Tan, Werner Brouwer & Leona Hakkaart. (2015) A noticeable difference? Productivity costs related to paid and unpaid work in economic evaluations on expensive drugs. The European Journal of Health Economics 17:4, pages 391-402.
Crossref
Crossref
Eusebi Chiner, Estrella Fernández-Fabrellas, Pedro Landete, Laura Novella, Mercedes Ramón, José Norberto Sancho-Chust, Cristina Senent & Javier Berraondo. (2016) Comparación de costes y resultados clínicos entre la administración hospitalaria o ambulatoria de omalizumab, en pacientes con asma grave no controlada. Archivos de Bronconeumología 52:4, pages 211-216.
Crossref
Crossref
Luis A. Pérez de Llano, Renata Villoro, María Merino, Maria del Carmen Gómez Neira, Camino Muñiz & Álvaro Hidalgo. (2016) Coste-efectividad de una unidad monográfica de asma. Archivos de Bronconeumología 52:4, pages 196-203.
Crossref
Crossref
Eusebi Chiner, Estrella Fernández-Fabrellas, Pedro Landete, Laura Novella, Mercedes Ramón, José Norberto Sancho-Chust, Cristina Senent & Javier Berraondo. (2016) Comparison of Costs and Clinical Outcomes Between Hospital and Outpatient Administration of Omalizumab in Patients With Severe Uncontrolled Asthma. Archivos de Bronconeumología (English Edition) 52:4, pages 211-216.
Crossref
Crossref
Luis A. Pérez de Llano, Renata Villoro, María Merino, Maria del Carmen Gómez Neira, Camino Muñiz & Álvaro Hidalgo. (2016) Cost Effectiveness of Outpatient Asthma Clinics. Archivos de Bronconeumología (English Edition) 52:4, pages 196-203.
Crossref
Crossref
Zafar Zafari, Mohsen Sadatsafavi, Carlo A. Marra, Wenjia Chen & J. Mark FitzGerald. (2016) Cost-Effectiveness of Bronchial Thermoplasty, Omalizumab, and Standard Therapy for Moderate-to-Severe Allergic Asthma. PLOS ONE 11:1, pages e0146003.
Crossref
Crossref
A S Kolbin, T L Galankin, M A Proskurin & Y E Balykina. (2015) Pharmacoeconomic analysis of using of tiotropium bromide (Spiriva® Respimat®) as adjunctive therapy in patients with asthma in the Russian Federation. Russian Journal of Allergy 12:5, pages 49-58.
Crossref
Crossref
Tianwen Lai, Shaobin Wang, Zhiwei Xu, Chao Zhang, Yun Zhao, Yue Hu, Chao Cao, Songmin Ying, Zhihua Chen, Wen Li, Bin Wu & Huahao Shen. (2015) Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis. Scientific Reports 5:1.
Crossref
Crossref
Rita Faria, Claire McKenna & Stephen Palmer. (2014) Optimizing the Position and Use of Omalizumab for Severe Persistent Allergic Asthma Using Cost-Effectiveness Analysis. Value in Health 17:8, pages 772-782.
Crossref
Crossref
Jenny Willson, Eric D. Bateman, Ian Pavord, Adam Lloyd, Tania Krivasi & Dirk Esser. (2014) Cost Effectiveness of Tiotropium in Patients with Asthma Poorly Controlled on Inhaled Glucocorticosteroids and Long-Acting β-Agonists. Applied Health Economics and Health Policy 12:4, pages 447-459.
Crossref
Crossref
Jonathan D. Campbell, R. Brett McQueen & Andrew Briggs. (2014) The “E” in Cost-Effectiveness Analyses. A Case Study of Omalizumab Efficacy and Effectiveness for Cost-Effectiveness Analysis Evidence. Annals of the American Thoracic Society 11:Supplement 2, pages S105-S111.
Crossref
Crossref
Roland Buhl, Andrea Gili Marco, Daniel Cohen & Giorgio Walter Canonica. (2014) Eligibility for treatment with omalizumab in Italy and Germany. Respiratory Medicine 108:1, pages 50-56.
Crossref
Crossref
Toshitaka Morishima, Hiroshi Ikai & Yuichi Imanaka. (2013) Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Asthma in Japan and the Value of Responder Prediction Methods Based on a Multinational Trial. Value in Health Regional Issues 2:1, pages 29-36.
Crossref
Crossref
Francesco Menzella, Nicola Facciolongo, Roberto Piro, Debora Formisano, Alberto Roggeri, Anna Simonazzi, Claudia Castagnetti, Cristiano Carbonelli & Luigi Zucchi. (2012) Clinical and pharmacoeconomic aspects of omalizumab: a 4-year follow-up. Therapeutic Advances in Respiratory Disease 6:2, pages 87-95.
Crossref
Crossref
J. D. Campbell, D. E. Spackman & S. D. Sullivan. (2010) The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective. Allergy 65:9, pages 1141-1148.
Crossref
Crossref
Thor‐Henrik Brodtkorb, Olle Zetterström & Gustav Tinghög. (2010) Cost‐effectiveness of clean air administered to the breathing zone in allergic asthma. The Clinical Respiratory Journal 4:2, pages 104-110.
Crossref
Crossref
Andrew Briggs, Karen Ritchie, Elisabeth Fenwick, Kalipso Chalkidou & Peter Littlejohns. (2010) Access with Evidence Development in the UK. PharmacoEconomics 28:2, pages 163-170.
Crossref
Crossref
A. Vergnenègre, K. Atsou & C. Chouaïd. (2010) Pharmacoéconomie pour le pneumologue. EMC - Pneumologie 7:1, pages 1-15.
Crossref
Crossref
J Jones, J Shepherd, D Hartwell, P Harris, K Cooper, A Takeda & P Davidson. (2009) Omalizumab for the treatment of severe persistent allergic asthma. Health Technology Assessment 13:Suppl 2, pages 31-39.
Crossref
Crossref
J. D. Campbell, D. E. Spackman & S. D. Sullivan. (2008) Health economics of asthma: assessing the value of asthma interventions. Allergy 63:12, pages 1581-1592.
Crossref
Crossref
R. Niven, K.F. Chung, Z. Panahloo, M. Blogg & G. Ayre. (2008) Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: An open-label study. Respiratory Medicine 102:10, pages 1371-1378.
Crossref
Crossref
S. D. Sullivan & F. Turk. (2008) An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma. Allergy 63:6, pages 670-684.
Crossref
Crossref
Paul Cornes. 2008. Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology. Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology
813
849
.
Jerry A. Krishnan & Michael Gould. (2007) Omalizumab for severe allergic asthma: Dollars and sense. Journal of Allergy and Clinical Immunology 120:5, pages 1015-1017.
Crossref
Crossref
Robert Kuhn. (2012) Immunoglobulin E Blockade in the Treatment of Asthma. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 27:10, pages 1412-1424.
Crossref
Crossref
R. Brown, F. Turk, P. Dale & J. Bousquet. (2007) Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy 62:2.
Crossref
Crossref
Paul P Belliveau & Monina R Lahoz. (2007) Treating Allergic Asthma with Omalizumab. Disease Management & Health Outcomes 15:3, pages 165-179.
Crossref
Crossref
. (2013) Omalizumab worth it in severe persistent asthma. PharmacoEconomics & Outcomes News 515:1, pages 12-12.
Crossref
Crossref